Premier Business Partner

Hawkins Food Ingredients Group

Check out our latest Edition!

 

Video

newswirelogo

  • NEW ORLEANS, Jan. 20, 2019 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 31, 2019 to file lead plaintiff applications in a securities class action lawsuit against Snap Inc. (NYSE: SNAP), if they purchased the Company’s shares between March 2, 2017, and August 10, 2017, inclusive (the “Class Period”) or traceable to its March 2, 2017 Initial Public Offering.  This action is pending in the United States District Court for the Central District of California.

  • NEW YORK, Jan. 20, 2019 (GLOBE NEWSWIRE) -- The global semiconductor dielectric etching equipment market is expected to reach USD 9.5 billion by 2024, growing at a CAGR of 4.8% from 2018 to 2024. The key factors driving the growth of global SDEE market include; miniaturization of semiconductor circuits and increasing demand for compact, high performance, and energy efficient electronic devices. Growing adoption of fine-shaped field effect transistors (FET) and rising demand for smart electronic devices such as smart phones, digital cameras, netbooks, PCs, and tablets are further propelling the growth of the global SDEE market.

  • KEMP, Texas, Jan. 20, 2019 (GLOBE NEWSWIRE) -- Larson Electronics, a Texas-based company with over 40 years of experience spearheading the industrial lighting sector, announced the release of a hazardous location metal halide light fixture producing 34,000 lumens of light output in a flood pattern with the ability to illuminate around 18,000 square feet of area. This light is available in pendant, ceiling or wall mount configurations and is Class I, Division 2 and Class II, Division 1 rated.

  • HONOLULU, Jan. 20, 2019 (GLOBE NEWSWIRE) -- Telstra and Infinera today unveiled a major boost to Telstra’s network services for customers in Asia Pacific, with a significant increase in fibre capacity to its subsea infrastructure using Infinera’s Infinite Capacity Engine 4 (ICE4).

  • ALPHARETTA, Ga., Jan. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.

Contact Us

Food and Drink Magazine
150 N. Michigan Ave., Suite 900
Chicago, IL 60601

  312.676.1100
  312.676.1101

Click here for a full list of contacts.

Latest Edition

Spread The Love

Back To Top